Abstract
It is doubtful that many in this room would quibble with the statement, in regard to warfarin dosage, that almost every physician appears to behave as if there were no published guidelines for prophylaxis and that he is, so to speak, “therapeutically on his own”. What this means in practical terms to individual patients in each of our own communities is that the therapeutic regimen offered depends on which physician is consulted. Moreover, within each category of practitioner, prophylaxis depends on the hospital entered, the service assigned, the specific attending physician responsible for the patient’s care, and, at some institutions, the house officer on duty at the time of admission. Private office and clinic outpatient management is no more standardized. In recognition of this absence of consensus it is hoped that several of the presentations to follow may provide some common ground concerning therapeutic regimens that will be of intrinsic value for decision making in cardiac and cerebral vascular disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
F.W. Schofield, A brief account of a disease of cattle simulating hemorrhagic septicaemia due to feeding sweet clover, Can Vet Rec 3:74(1922).
K. P. Link, Anticoagulant from spoiled sweet clover hay, Harvey Lect 39:162(1944).
A. J. Quick, The prothrombin in hemophilia and in obstructive jaundice, J Biol Chem, 109:lxxiii(1935).
J. B. Bingham, O. O. Meyer, and F.J. Pohle, Studies on the hemorrhagic agent 3,3′-methylenebis (4-Hydroxycoumarin). I. Its effect on the prothrombin and coagulation time of the blood of dogs and humans, Am J Med Sci, 202:563(1941).
H. R. Butt, E.V. Allen, and J. L. Bollman, A preChapaution from spoiled sweet clover [3,3′-methylenebis-(4-hydroxycoumarin)] which prolongs coagulation and prothrombin time of the blood: preliminary report of experimental and clinical studies, Proc Staff Meet Mayo Clin, 16:388(1941).
A. Prandoni, and I. S. Wright, The anticoagulants heparin and the dicumarin -3, 3′-methylenebis-(4-hydroxycoumarin). Bull NY Acad Med, 18:433(1942).
P. B. Medawar, The Limits of Science, Harper and Row, New York (1984).
I. S. Wright, C. D. Marple, and D. F. Beck, Myocardial infarction: its clinical manifestations and treatment with anticoagulants. A study of 1031 cases, Grune and Stratton, New York (1954).
G. deTakats, Anticoagulant therapy in surgery, JAMA, 142:527(1950).
D. A. Taberner, L. Poller, R. W. Burslem, and J. B. Jones, Oral anticoagulants controlled by the British comChapautive thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis. Br Med J 1:272(1978).
R. Hull, J. Hirsh, R. Jay, C. Carter, C. England, R. M. Gent, A. G. Turpie, D. McLoughlin, P. Dodd, M. Thomas, G. Raspob, and P. Ockefford, Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis, N Engl J Med 307:1676(1982).
C. W. Francis, V. J. Marder, C. M. Evarts, and S. Yaukoolbodi, Two-step warfarin therapy: prevention of postoperative venous thrombosis without excessive bleeding. JAMA 249:374(1983).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer Science+Business Media New York
About this chapter
Cite this chapter
Wessler, S. (1987). What’s the Dose?. In: Wessler, S., Becker, C.G., Nemerson, Y. (eds) The New Dimensions of Warfarin Prophylaxis. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-5985-3_11
Download citation
DOI: https://doi.org/10.1007/978-1-4757-5985-3_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-5987-7
Online ISBN: 978-1-4757-5985-3
eBook Packages: Springer Book Archive